Key clinical point: Mutations in certain tumor suppressor genes are prognostic for OS in mNSCLC.
Major finding: ORRs for durvalumab + tremelimumab treated patients with ARID1am vs. ARID1awt were 51.3% vs. 19.4%, respectively.
Study details: An analysis of 943 samples from the open-label phase 3 MYSTIC trial.
Disclosures: The MYSTIC trial was sponsored by AstraZeneca. Dr. Rizvi disclosed royalties related to intellectual property/patents filed by MSKCC and Personal Genome Diagnostics.
Rizvi N et al. WCLC 2019: Abstract OA04.07.